The α2-adrenergic receptor agonist, clonidine, reduces alcohol drinking in alcohol-preferring (P) rats
- PMID: 25085719
- PMCID: PMC4163132
- DOI: 10.1016/j.alcohol.2014.07.002
The α2-adrenergic receptor agonist, clonidine, reduces alcohol drinking in alcohol-preferring (P) rats
Abstract
Evidence suggests that noradrenergic signaling may play a role in mediating alcohol-drinking behavior in both rodents and humans. We have investigated this possibility by administering clonidine to alcohol-drinking rats selectively bred for alcohol preference (P line). Clonidine is an α2-adrenergic receptor agonist which, at low doses, inhibits noradrenergic signaling by decreasing norepinephrine release from presynaptic noradrenergic neurons. Adult male P rats were given 24 h access to food and water and scheduled access to a 15% (v/v) alcohol solution for 2 h daily. Rats received intra-peritoneal (IP) injections with clonidine (0, 10, 20, 40, or 80 μg/kg body weight [BW], 10-11 rats/treatment group) once/day at 30 min prior to onset of the daily 2 h alcohol access period for 2 consecutive days. Clonidine, in doses of 40 or 80 μg/kg BW, significantly reduced alcohol intake on both days of treatment (p<0.001). Two weeks later, rats were treated with clonidine for 5 consecutive days and clonidine, in doses of 40 or 80 μg/kg BW, reduced alcohol intake on all 5 treatment days (p < 0.001). Clonidine did not alter water consumption during the daily 2 h free-choice between alcohol and water. In a separate group of male P rats, clonidine (40 μg/kg BW) suppressed intake of a saccharin solution (0.04 g/L). These results are consistent with and complement our previous findings that the α1-adrenergic receptor antagonist, prazosin, decreases voluntary alcohol drinking in alcohol-preferring rats, but suggests that effects of clonidine may not be specific for alcohol. The results suggest that although activation of the noradrenergic system plays an important role in mediating voluntary alcohol drinking, care is needed in selecting which drugs to use to suppress central noradrenergic signaling in order to maximize the selectivity of the drugs for treating alcohol-use disorders.
Keywords: Alcohol; Clonidine; Ethanol; Noradrenergic; Norepinephrine; P rat.
Published by Elsevier Inc.
Figures





References
-
- Aghajanian GK, VanderMaelen CP. alpha 2-adrenoceptor-mediated hyperpolarization of locus coeruleus neurons: intracellular studies in vivo. Science. 1982;215:1394–1396. - PubMed
-
- Amit Z, Brown ZW, Levitan DE, Ogren SO. Noradrenergic mediation of the positive reinforcing properties of ethanol: I. Suppression of ethanol consumption in laboratory rats following dopamine-beta-hydroxylase inhibition. Archives Internationales de Pharmacodynamie et de Thérapie. 1977;230:65–75. - PubMed
-
- Arndts D, Doevendans J, Kirsten R, Heintz B. New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man. European Journal of Clinical Pharmacology. 1983;24:21–30. - PubMed
-
- Björkqvist SE. Clonidine in alcohol withdrawal. Acta Psychiatrica Scandinavica. 1975;52:256–263. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AA013881/AA/NIAAA NIH HHS/United States
- AA017839/AA/NIAAA NIH HHS/United States
- R01 AA010709/AA/NIAAA NIH HHS/United States
- P60 AA007611/AA/NIAAA NIH HHS/United States
- AA10709/AA/NIAAA NIH HHS/United States
- AA018604/AA/NIAAA NIH HHS/United States
- AA10567/AA/NIAAA NIH HHS/United States
- U24 AA015512/AA/NIAAA NIH HHS/United States
- AA007611/AA/NIAAA NIH HHS/United States
- AA13881/AA/NIAAA NIH HHS/United States
- P20 AA017839/AA/NIAAA NIH HHS/United States
- R01 AA018604/AA/NIAAA NIH HHS/United States
- P50 AA007611/AA/NIAAA NIH HHS/United States
- R01 AA010567/AA/NIAAA NIH HHS/United States